Las Vegas, NV -- (SBWIRE) -- 09/21/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: ISIS Pharmaceuticals, Inc.(NASDAQ:ISIS), Array Biopharma Inc(NASDAQ:ARRY) , Baxter International Inc.(NYSE:BAX) , Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA)
ISIS Pharmaceuticals, Inc.(NASDAQ:ISIS) managed to keep its fall at -0.58% on above-normal volume of 3.64 million shares. The stock settled at $36.06 after floating in a range of $35.16 to $37.09. Its latest price was $36.06, reaching market capitalization of $4.16 million. Its 52-week range has been $7.55 to $37.09. Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company?s flagship product, KYNAMRO injection.
Has ISIS Found The Bottom and Ready To Move Up? Find Out Here
Array Biopharma Inc(NASDAQ:ARRY) traded down on a volume of 4.63 million, higher than its standard daily volume. Shares have dropped -1.49% to $6.30. Over the last twelve months, the stock has added 8.53% and faced a best price of $7.10. Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America.
Has ARRY Found The Bottom And Ready To Gain Momentum? Find Out Here
Baxter International Inc.(NYSE:BAX) settled -0.86% lower at $71.58 on above-normal volume of 3.36 million shares during the last trading day. The stock has its 12-month high at $74.60 and 52-week low price was $59.61. It traded in a range of $71.51 to $72.62 during the last trading day. Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Why Should Investors Buy BAX After the Recent Fall ? Just Go Here and Find Out
Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA) saw its price fall on above-normal volume, as 3.37 million shares changed hands when compared with its average daily volume of 2.74million shares. The stock was down -5.89% to $.0280. It has fallen/gained over the last 12 months, dropping -14.34% and marked new low $15.35. ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.
Will ARIA Get Buyers Even After The Recent Rally? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)